Boston Partners trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,098,830 shares of the company’s stock after selling 14,975 shares during the period. Boston Partners’ holdings in Johnson & Johnson were worth $290,760,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares during the period. Deutsche Bank AG grew its holdings in shares of Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Johnson & Johnson by 11.5% in the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after buying an additional 1,530,070 shares during the period. Amundi increased its stake in shares of Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in Johnson & Johnson by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after acquiring an additional 148,497 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of recent research reports. Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a research note on Thursday, October 15th. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 14th. Erste Group Bank downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. Finally, Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.
View Our Latest Stock Analysis on Johnson & Johnson
Recent Johnson & Johnson Headlines
Investors following JNJ have been watching these headlines:
- Positive Sentiment: Prostate cancer data presented at ESMO were described as “immaculate,” suggesting Johnson & Johnson’s $3.05 billion Halda acquisition is showing clinical promise. The data could strengthen the company’s oncology pipeline, though the program remains subject to further development. Article
- Positive Sentiment: Memorial Hermann-Texas Medical Center will be the first hospital to install the OTTAVA robotic surgical system as part of an early-access commercial launch. This marks a step toward monetizing the platform following its FDA De Novo authorization. Article
- Positive Sentiment: Johnson & Johnson filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes. Two Phase 3 studies showed symptom improvement versus placebo; approval would add a potential fifth adult indication, but remains uncertain. Article
Johnson & Johnson Trading Down 2.1%
Shares of JNJ stock opened at $267.02 on Friday. Johnson & Johnson has a fifty-two week low of $199.90 and a fifty-two week high of $290.25. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a 50 day simple moving average of $267.43 and a two-hundred day simple moving average of $250.79. The company has a market cap of $642.80 billion, a P/E ratio of 40.46, a PEG ratio of 2.74 and a beta of 0.22.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.
Insider Buying and Selling
In related news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Further Reading
- Five stocks we like better than Johnson & Johnson
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
